{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T09:00:58Z","timestamp":1780131658168,"version":"3.54.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10096-026-05420-9","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:21:56Z","timestamp":1771381316000},"page":"1225-1236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A systematic review of data on the resistance of uropathogens to sulopenem"],"prefix":"10.1007","volume":"45","author":[{"given":"Matthew E.","family":"Falagas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios S.","family":"Kontogiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Ragias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Filippou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"5420_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30102126","volume":"30","author":"A Rusu","year":"2025","unstructured":"Rusu A, Oancea O-L, Donici E, Uncu L (2025) Recent developments in penem antibiotics: structural and therapeutic perspectives. Molecules 30:2126. https:\/\/doi.org\/10.3390\/molecules30102126","journal-title":"Molecules"},{"key":"5420_CR2","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1128\/AAC.37.7.1547","volume":"37","author":"M Minamimura","year":"1993","unstructured":"Minamimura M, Taniyama Y, Inoue E, Mitsuhashi S (1993) In vitro antibacterial activity and beta-lactamase stability of CP-70,429 a new penem antibiotic. Antimicrob Agents Chemother 37:1547\u20131551. https:\/\/doi.org\/10.1128\/AAC.37.7.1547","journal-title":"Antimicrob Agents Chemother"},{"key":"5420_CR3","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1128\/AAC.33.8.1160","volume":"33","author":"T Gootz","year":"1989","unstructured":"Gootz T, Retsema J, Girard A, Hamanaka E, Anderson M, Sokolowski S (1989) In vitro activity of CP-65,207, a new penem antimicrobial agent, in comparison with those of other agents. Antimicrob Agents Chemother 33:1160\u20131166","journal-title":"Antimicrob Agents Chemother"},{"key":"5420_CR4","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1128\/AAC.35.4.665","volume":"35","author":"G Foulds","year":"1991","unstructured":"Foulds G, Knirsch A, Lazar J, Tensfelt T, Gerber N (1991) Pharmacokinetics of the penem CP-65,207 and its separate stereoisomers in humans. Antimicrob Agents Chemother 35:665\u2013671","journal-title":"Antimicrob Agents Chemother"},{"key":"5420_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40265-022-01688-1","volume":"82","author":"GG Zhanel","year":"2022","unstructured":"Zhanel GG, Pozdirca M, Golden AR, Lawrence CK, Zelenitsky S, Berry L, Schweizer F, Bay D, Adam H, Zhanel MA et al (2022) Sulopenem: an intravenous and oral penem for the treatment of urinary tract infections due to multidrug-resistant bacteria. Drugs 82:533\u2013557. https:\/\/doi.org\/10.1007\/s40265-022-01688-1","journal-title":"Drugs"},{"key":"5420_CR6","unstructured":"U.S.Food and Drug Administration (2024) Center for drug evaluation and research FDA approves new treatment for uncomplicated urinary tract infections in adult women who have limited or no alternative oral antibiotic treatment options. US Food Drug Adm. Silver Spring MD USA. FDA Drug News (approved 25 October 2024). Available at: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-new-treatment-uncomplicated-urinary-tract-infections-adult-women-who-have-limited-or-no"},{"key":"5420_CR7","doi-asserted-by":"publisher","DOI":"10.1177\/00185787251324844","author":"DE Baker","year":"2025","unstructured":"Baker DE, Levien TL (2025) Sulopenem etzadroxil\/probenecid. Hosp Pharm. https:\/\/doi.org\/10.1177\/00185787251324844","journal-title":"Hosp Pharm"},{"key":"#cr-split#-5420_CR8.1","unstructured":"U.S.Food and Drug Administration (2024) ORLYNVAHTM (Sulopenem Etzadroxil and Probenecid) tablets, for oral use: highlights of prescribing information"},{"key":"#cr-split#-5420_CR8.2","unstructured":"U.S. Food and Drug Administration: Silver Spring, MD, USA .Full prescribing label, revised October 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/213972s000lbl.pdf"},{"key":"5420_CR9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1080\/13543784.2025.2532443","volume":"34","author":"LT Romanos","year":"2025","unstructured":"Romanos LT, Kontogiannis DS, Tsiampali C, Tzvetanova ID, Falagas ME (2025) Antibiotics and non-traditional antimicrobial agents for Pseudomonas aeruginosa in clinical phases 1, 2, and 3 trials. Expert Opin Investig Drugs 34:639\u2013653. https:\/\/doi.org\/10.1080\/13543784.2025.2532443","journal-title":"Expert Opin Investig Drugs"},{"key":"5420_CR10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1080\/13543784.2025.2552846","volume":"34","author":"DS Kontogiannis","year":"2025","unstructured":"Kontogiannis DS, Romanos LT, Tzvetanova ID, Voulgaris GL, Falagas ME (2025) Antibiotics and non-traditional antimicrobial agents for carbapenem-resistant Acinetobacter baumannii in phase 1, 2, and 3 clinical trials. Expert Opin Investig Drugs 34:705\u2013716. https:\/\/doi.org\/10.1080\/13543784.2025.2552846","journal-title":"Expert Opin Investig Drugs"},{"key":"5420_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ajic.2023.08.013","volume":"52","author":"D Khatri","year":"2024","unstructured":"Khatri D, Freeman C, Falconer N, de Camargo Catapan S, Gray LC, Paterson DL (2024) Clinical impact of antibiograms as an intervention to optimize antimicrobial prescribing and patient outcomes\u2014a systematic review. Am J Infect Control 52:107\u2013122. https:\/\/doi.org\/10.1016\/j.ajic.2023.08.013","journal-title":"Am J Infect Control"},{"key":"5420_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens14040307","volume":"14","author":"M Sargianou","year":"2025","unstructured":"Sargianou M, Stathopoulos P, Vrysis C, Tzvetanova ID, Falagas ME (2025) New \u03b2-lactam\/\u03b2-lactamase inhibitor combination antibiotics. Pathogens 14:307. https:\/\/doi.org\/10.3390\/pathogens14040307","journal-title":"Pathogens"},{"key":"5420_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens14020168","volume":"14","author":"A Katsarou","year":"2025","unstructured":"Katsarou A, Stathopoulos P, Tzvetanova ID, Asimotou C-M, Falagas ME (2025) \u03b2-lactam\/\u03b2-lactamase inhibitor combination antibiotics under development. Pathogens 14:168. https:\/\/doi.org\/10.3390\/pathogens14020168","journal-title":"Pathogens"},{"key":"5420_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab466.1266","volume":"8","author":"M Dunne","year":"2021","unstructured":"Dunne M, Aronin SI, Halasohoris SA, Pysz LM, Lembirik S, Meinig JM (2021) 1072. In vitro antibacterial susceptibility testing of sulopenem against category A and B bio-threat bacterial pathogens. Open Forum Infect Dis 8:S628\u2013S628. https:\/\/doi.org\/10.1093\/ofid\/ofab466.1266","journal-title":"Open Forum Infect Dis"},{"key":"5420_CR15","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1128\/AAC.01557-08","volume":"53","author":"LM Ednie","year":"2009","unstructured":"Ednie LM, Appelbaum PC (2009) Antianaerobic activity of sulopenem compared to six other agents. Antimicrob Agents Chemother 53:2163\u20132170","journal-title":"Antimicrob Agents Chemother"},{"key":"5420_CR16","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00547-23","volume":"67","author":"C Le Terrier","year":"2023","unstructured":"Le Terrier C, Nordmann P, Bouvier M, Poirel L (2023) Impact of acquired broad-spectrum \u03b2-lactamases on susceptibility to oral penems\/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam \u03b2-lactamase inhibitors in Escherichia coli. Antimicrob Agents Chemother 67:e00547-23","journal-title":"Antimicrob Agents Chemother"},{"key":"5420_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01898-24","volume":"13","author":"JM Maher","year":"2025","unstructured":"Maher JM, Huband MD, Lindley JM, Rhomberg PR, Aronin SI, Puttagunta S, Castanheira M (2025) Characterization of sulopenem antimicrobial activity using in vitro time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against Escherichia coli and Klebsiella pneumoniae isolates. Microbiol Spectr 13:e01898-24","journal-title":"Microbiol Spectr"},{"key":"5420_CR18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.11553\/antibiotics1968b.49.367","volume":"49","author":"K Watanabe","year":"1996","unstructured":"Watanabe K, Kato N, Tanaka K, Tanaka Y, Kato H, Ueno K (1996) In vitro activities of sulopenem, a new parenteral penem, against anaerobes. Jpn J Antibiot 49:367\u2013376. https:\/\/doi.org\/10.11553\/antibiotics1968b.49.367","journal-title":"Jpn J Antibiot"},{"key":"5420_CR19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jgar.2025.06.013","volume":"44","author":"SI Aronin","year":"2025","unstructured":"Aronin SI, Huband MD, Becker H, Fedler KA, Dunne MW (2025) In vitro activity of sulopenem and comparator agents against US enterobacterales clinical isolates collected during the SENTRY antimicrobial surveillance program in 2023. J Glob Antimicrob Resist 44:152\u2013159. https:\/\/doi.org\/10.1016\/j.jgar.2025.06.013","journal-title":"J Glob Antimicrob Resist"},{"key":"5420_CR20","unstructured":"Dunne M, Huband M, Flamm R, Aronin S, Puttagunta S (2018) Prediction of sulopenem activity against enterobacteriaceae using ertapenem as a surrogate. In: Proceedings of the American society for microbiology (ASM) MICROBE Meeting; Poster 570; Atlanta, GA, USA, pp 7\u201310"},{"key":"5420_CR21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01832-18","volume":"63","author":"JA Karlowsky","year":"2019","unstructured":"Karlowsky JA, Adam HJ, Baxter MR, Denisuik AJ, Lagac\u00e9-Wiens PRS, Walkty AJ, Puttagunta S, Dunne MW, Zhanel GG (2019) In vitro activity of sulopenem, an oral penem, against urinary isolates of Escherichia coli. Antimicrob Agents Chemother 63:e01832-18. https:\/\/doi.org\/10.1128\/AAC.01832-18","journal-title":"Antimicrob Agents Chemother"},{"key":"5420_CR22","first-page":"352","volume":"49","author":"A Komoto","year":"1996","unstructured":"Komoto A, Otsuki M, Nishino T (1996) In vitro and in vivo antibacterial activities of sulopenem, a new penem antibiotic. Jpn J Antibiot 49:352\u2013366","journal-title":"Jpn J Antibiot"},{"key":"5420_CR23","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1093\/jac\/dkad099","volume":"78","author":"JM Maher","year":"2023","unstructured":"Maher JM, Huband MD, Blankers CG, Puttagunta S, Aronin SI, Castanheira M (2023) In vitro activity of sulopenem and comparator agents against enterobacterales and anaerobic clinical isolates collected during the SENTRY antimicrobial surveillance program. J Antimicrob Chemother 78:1406\u20131414. https:\/\/doi.org\/10.1093\/jac\/dkad099","journal-title":"J Antimicrob Chemother"},{"key":"5420_CR24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.11553\/antibiotics1968b.49.303","volume":"49","author":"M Nagashima","year":"1996","unstructured":"Nagashima M, Goto S, Yoshida T, Matsunaga T, Shimohira H, Ogawa M (1996) In vitro and in vivo activities of sulopenem compared with those of imipenem and cephalosporins. Jpn J Antibiot 49:303\u2013323. https:\/\/doi.org\/10.11553\/antibiotics1968b.49.303","journal-title":"Jpn J Antibiot"},{"key":"5420_CR25","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jgar.2025.08.002","volume":"44","author":"BR O\u2019Neill","year":"2025","unstructured":"O\u2019Neill BR, Ginn A, Jayawardena M, Sandaradura I (2025) Susceptibility of multidrug-resistant Escherichia coli and Klebsiella pneumoniae to oral antibiotics in Australia. J Glob Antimicrob Resist 44:435\u2013441. https:\/\/doi.org\/10.1016\/j.jgar.2025.08.002","journal-title":"J Glob Antimicrob Resist"},{"key":"5420_CR26","doi-asserted-by":"crossref","unstructured":"Puttagunta S, Aronin S, Huband M, Flamm RK, Dunne M (2018) 1363. Sulopenem Activity against Enterobacteriaceae Isolates from Patients with Urinary Tract Infection or Intra-Abdominal Infection.; Oxford University Press US, Vol 5, pp S417\u2013S417","DOI":"10.1093\/ofid\/ofy210.1194"},{"key":"5420_CR27","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1093\/jac\/dkac333","volume":"77","author":"AJ Walkty","year":"2022","unstructured":"Walkty AJ, Karlowsky JA, Baxter MR, Lagace-Wiens PRS, Adam HJ, Zhanel GG (2022) In vitro activity of sulopenem against 1880 bacterial pathogens isolated from Canadian patients with urinary tract infections (CANWARD, 2014\u201321). J Antimicrob Chemother 77:3414\u20133420. https:\/\/doi.org\/10.1093\/jac\/dkac333","journal-title":"J Antimicrob Chemother"},{"key":"5420_CR28","doi-asserted-by":"publisher","first-page":"324","DOI":"10.11553\/antibiotics1968b.49.324","volume":"49","author":"T Yoshida","year":"1996","unstructured":"Yoshida T, Tateda E, Hiramatsu K, Yokota K (1996) Sulopenem basic and bacteriological studies on antibacterial activity. Jpn J Antibiot 49:324\u2013337. https:\/\/doi.org\/10.11553\/antibiotics1968b.49.324","journal-title":"Jpn J Antibiot"},{"key":"5420_CR29","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/S1473-3099(20)30003-7","volume":"20","author":"R Laxminarayan","year":"2020","unstructured":"Laxminarayan R, Van Boeckel T, Frost I, Kariuki S, Khan EA, Limmathurotsakul D, Larsson DGJ, Levy-Hara G, Mendelson M, Outterson K et al (2020) The Lancet infectious diseases commission on antimicrobial resistance: 6 years later. Lancet Infect Dis 20:e51\u2013e60. https:\/\/doi.org\/10.1016\/S1473-3099(20)30003-7","journal-title":"Lancet Infect Dis"},{"key":"5420_CR30","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00042-24","volume":"0","author":"S Sayood","year":"2025","unstructured":"Sayood S, Neuner E, Dumm R, Gandra S (2025) The oral penems and carbapenems. Clin Microbiol Rev 0:e00042-24. https:\/\/doi.org\/10.1128\/cmr.00042-24","journal-title":"Clin Microbiol Rev"},{"key":"5420_CR31","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1128\/aac.00296-11","volume":"55","author":"KM Papp-Wallace","year":"2011","unstructured":"Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA (2011) Carbapenems: past, present, and future. Antimicrob Agents Chemother 55:4943\u20134960. https:\/\/doi.org\/10.1128\/aac.00296-11","journal-title":"Antimicrob Agents Chemother"},{"key":"5420_CR32","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research Antibacterial Susceptibility Test Interpretive Criteria. US Food Drug Adm. Silver Spring MD USA 2025."},{"key":"5420_CR33","unstructured":"EUCAST: Clinical breakpoints and dosing of antibiotics available online: https:\/\/www.eucast.org\/clinical_breakpoints. Accessed 6 Oct 2025"},{"key":"5420_CR34","first-page":"210","volume":"27","author":"MP Weinstein","year":"2018","unstructured":"Weinstein MP, Limbago B, Patel J, Mathers A, Campeau S, Mazzulli T, Eliopoulos G, Patel R, Galas M, Richter S (2018) M100 performance standards for antimicrobial susceptibility testing. Clin Lab Stand Inst 27:210\u2013214","journal-title":"Clin Lab Stand Inst"},{"key":"5420_CR35","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","volume":"67","author":"GG Zhanel","year":"2007","unstructured":"Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA (2007) Comparative review of the carbapenems. Drugs 67:1027\u20131052. https:\/\/doi.org\/10.2165\/00003495-200767070-00006","journal-title":"Drugs"},{"key":"5420_CR36","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1128\/aac.45.7.1964-1971.2001","volume":"45","author":"K Okamoto","year":"2001","unstructured":"Okamoto K, Gotoh N, Nishino T (2001) Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay. Antimicrob Agents Chemother 45:1964\u20131971. https:\/\/doi.org\/10.1128\/aac.45.7.1964-1971.2001","journal-title":"Antimicrob Agents Chemother"},{"key":"5420_CR37","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1128\/AAC.00285-06","volume":"50","author":"FM Kaczmarek","year":"2006","unstructured":"Kaczmarek FM, Dib-Hajj F, Shang W, Gootz TD (2006) High-Level Carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of blaACT-1 \u03b2-Lactamase production, Porin OmpK35\/36 insertional inactivation, and down-regulation of the phosphate transport Porin PhoE. Antimicrob Agents Chemother 50:3396\u20133406. https:\/\/doi.org\/10.1128\/AAC.00285-06","journal-title":"Antimicrob Agents Chemother"},{"key":"5420_CR38","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1093\/ajhp\/zxaf220","volume":"83","author":"E Ocheretyaner","year":"2025","unstructured":"Ocheretyaner E, Melgar K, Kalabalik-Hoganson J (2025) Sulopenem etzadroxil and probenecid: a drug review of a novel oral penem active against ESBL-producing bacteria. Am J Health-Syst Pharm 83:e6\u2013e11. https:\/\/doi.org\/10.1093\/ajhp\/zxaf220","journal-title":"Am J Health-Syst Pharm"},{"key":"5420_CR39","doi-asserted-by":"publisher","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ (2023) Infectious diseases society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections. Clin Infect Dis ciad428. https:\/\/doi.org\/10.1093\/cid\/ciad428","DOI":"10.1093\/cid\/ciad428"},{"key":"5420_CR40","first-page":"167","volume":"109","author":"PK Kurotschka","year":"2024","unstructured":"Kurotschka PK, G\u00e1gyor I, Ebell MH (2024) Acute uncomplicated UTIs in adults: rapid evidence review. Am Fam Physician 109:167\u2013174","journal-title":"Am Fam Physician"},{"key":"5420_CR41","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/00325481.2019.1680052","volume":"132","author":"MS Bader","year":"2020","unstructured":"Bader MS, Loeb M, Leto D, Brooks AA (2020) Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Postgrad Med 132:234\u2013250. https:\/\/doi.org\/10.1080\/00325481.2019.1680052","journal-title":"Postgrad Med"},{"key":"5420_CR42","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2400414","volume":"4","author":"S Puttagunta","year":"2025","unstructured":"Puttagunta S, Aronin SI, Gupta J, Das AF, Gupta K, Dunne MW (2025) Sulopenem versus amoxicillin\/clavulanate for the treatment of uncomplicated urinary tract infection. NEJM Evid 4:EVIDoa2400414. https:\/\/doi.org\/10.1056\/EVIDoa2400414","journal-title":"NEJM Evid"},{"key":"5420_CR43","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/cid\/ciac704","volume":"76","author":"MW Dunne","year":"2023","unstructured":"Dunne MW, Aronin SI, Das AF, Akinapelli K, Breen J, Zelasky MT, Puttagunta S (2023) Sulopenem for the treatment of complicated urinary tract infections including pyelonephritis: a phase 3, randomized trial. Clin Infect Dis 76:78\u201388. https:\/\/doi.org\/10.1093\/cid\/ciac704","journal-title":"Clin Infect Dis"},{"key":"5420_CR44","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.cmi.2024.10.025","volume":"31","author":"MW Dunne","year":"2025","unstructured":"Dunne MW, Aronin SI, Das AF, Akinapelli K, Breen JD, Zelasky MT, Puttagunta S (2025) A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intra-abdominal infections. Clin Microbiol Infect 31:396\u2013401. https:\/\/doi.org\/10.1016\/j.cmi.2024.10.025","journal-title":"Clin Microbiol Infect"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05420-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-026-05420-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05420-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T08:04:02Z","timestamp":1780128242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-026-05420-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5420"],"URL":"https:\/\/doi.org\/10.1007\/s10096-026-05420-9","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}